title: [Management of the atypical antipsychotic olanzapine in a clinical environment with particular regard to therapeutic drug monitoring (TDM) in a German State hospital].
abstract: OBJECTIVE
  Therapeutic drug monitoring (TDM) has been established at BKH Augsburg (psychiatric district hospital) since January 2001. According to Olanzapine product information the following illustration shows the evaluation (n = 216) of various parameters of the TDM requirements of Olanzapine.
  
  
  METHODS
  Items examined include "classification according to diagnoses", "reason for requirement", "severity of disease", "therapeutic effect" and "side-effects". In addition, serum concentration, daily dosage, clinical assessment (Brief Psychiatric Rating Scale), age, height and weight of patients will be presented.
  
  
  RESULTS
  Clearly sick patients, 52 % of them between 20 and 30 years old, were less compliant and achieved only a moderate therapeutic effect.
  
  
  CONCLUSIONS
  TDM is mainly assessed to control compliance. However, more specific and more personalized TDM would be more useful.
authors.affiliation: Bezirkskrankenhaus Augsburg. rita.lutz@bkh-augsburg.de
authors.forename: Rita
authors.initials: R
authors.lastname: Lutz
authors.forename: Oliver
authors.initials: O
authors.lastname: Köhnlein
authors.forename: Max
authors.initials: M
authors.lastname: Schmauss
authors.forename: Thomas
authors.initials: T
authors.lastname: Messer
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D012189:Retrospective Studies; D018967:Risperidone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine